Latest News

  • Alkermes Announces Positive Topline Results From FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Read More
  • Alkermes Announces Initiation of Clinical Study Evaluating Metabolic Profile of ALKS 3831 for Treatment of Schizophrenia Read More
  • Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016 Read More


Learn more Learn More Alkermes PLC Investor Relations

Working at Alkermes

Join Our Team Join Our Team Working at Alkermes